Phase I trial of Uracil-Tegafur (UFT) plus oral leucovorin: 14-day schedule

Abstract
We previously reported results of a Phase II trial of UFT [Taiho Pharmaceutical Ltd., Tokyo, Japan; (BMS-200604) Bristol-Myers Squibb, Princeton, NJ], an oral 4:1 molar concentration of uracil and...